SCHEMBL1243420

SCHEMBL1243420

OS1(O)CCCN1C(c1ccc(F)cc1)C(c1cccnc1)c1cccnc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.40
TP53 P04637 4/20 0.39
LMNA P02545 4/20 0.39
MAPT P10636 3/20 0.39
SLC1A3 P43003 1/20 0.39
SLC1A2 P43004 1/20 0.39
SLC1A1 P43005 1/20 0.39
KCNH2 Q12809 1/20 0.39
TSHR P16473 2/20 0.39
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
ALDH1A1 P00352 1/20 0.38
CYP19A1 P11511 1/20 0.38
CYP11B1 P15538 1/20 0.38
CYP11B2 P19099 1/20 0.38
MAPK1 P28482 1/20 0.37
THRB P10828 2/20 0.37
GAA P10253 1/20 0.37
KCNE1 P15382 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1243418 0.86 CYP19A1 (0.42) POLBTP53LMNAMAPTSLC1A3
SCHEMBL1240966 0.79 MGLL (0.43) KCNH2MEN1KMT2AALDH1A1CYP19A1
SCHEMBL1240440 0.78 KCNA5 (0.45) POLBLMNAKCNH2TSHRMEN1
SCHEMBL1242866 0.73 MAPT (0.51) POLBMAPTKCNH2TSHRMEN1
SCHEMBL1242199 0.72 CYP11B1 (0.47) POLBTP53LMNAMAPTSLC1A3
SCHEMBL1378412 0.71 KCNA5 (0.56) POLBMEN1KMT2ASMN1; SMN2CYP19A1
SCHEMBL3888426 0.71 KCNA5 (0.56) POLBMEN1KMT2ASMN1; SMN2CYP19A1
SCHEMBL1243098 0.70 POLB (0.54) POLBTSHRSMN1; SMN2CYP19A1CYP11B1
SCHEMBL1243214 0.70 KCNA5 (0.49) POLBTP53LMNAMAPTKCNH2
SCHEMBL1243229 0.69 CYP19A1 (0.42) POLBTP53LMNAMAPTSLC1A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1781635-B1 POTASSIUM CHANNEL INHIBITORS MERCK SHARP & DOHME (US) 2012-06-13 EP claimed
US-7879839-B2 For treatment and prevention of cardiac arrhythmias; (+-)-2-Morpholin-4-yl-2-phenyl-1,1-dipyridin-3-yl-ethanol; (+-)-2-[(2-methoxyethyl)(methyl)amino]-2-phenyl-1,1-dipyridin-3-ylethanol MERCK SHARP & DOHME CORP. (US) 2011-02-01 US claimed
US-20080090794-A1 Potassium Channel Inhibitors MERCK SHARP & DOHME LLC 2008-04-17 US claimed
EP-1781635-B1 POTASSIUM CHANNEL INHIBITORS MERCK SHARP & DOHME (US) 2012-06-13 EP disclosed
US-7879839-B2 For treatment and prevention of cardiac arrhythmias; (+-)-2-Morpholin-4-yl-2-phenyl-1,1-dipyridin-3-yl-ethanol; (+-)-2-[(2-methoxyethyl)(methyl)amino]-2-phenyl-1,1-dipyridin-3-ylethanol MERCK SHARP & DOHME CORP. (US) 2011-02-01 US disclosed
US-20080090794-A1 Potassium Channel Inhibitors MERCK SHARP & DOHME LLC 2008-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080090794-A1 Potassium Channel Inhibitors KCNJ2, KCNQ2, KCNH2 POLB 4819/4885TP53 4783/4885LMNA 815/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.